Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience

Autor:	Değertekin, Bülent, Demir, Mehmet, Akarca, Ulus S., Kani, Haluk Tarık, Uçbilek, Enver, Yıldırım, Emre, Güzelbulut, Fatih, Balkan, Ayhan, Vatansever, Sezgin, Danış, Nilay, Demircan, Melek, Soylu, Aliye, Yaras, Serkan, Kartal, Aysun, Kefeli, Ayşe, Gündüz, Feyza, Yalçın, Kendal, Erarslan, Elife, Aladag, Murat, Harputluoğlu, Murat, Özakyol, Aysegül, Temel, Tuncer, Akarsu, Mesut, Sümer, Hale, Akın, Mete, Albayrak, Bülent, Şen, İlker, Alkım, Hüseyin, Uyanıkoğlu, Ahmet, Irak, Kader, Öztaşkın, Sinem, Uğurlu, Çağrı Burak, Günes, Şevkican, Gürel, Selim, Nuriyev, Kenan, İnci, İsmail, Kaçar, Sabite, Dinçer, Dinç, Doğanay, Levent, Göktürk, Hüseyin Savaş, Mert, Ali, Coşar, Arif Mansur, Dursun, Hakan, Atalay, Roni, Akbulut, Sabiye, Balkan, Yasemin, Köklü, Hayrettin, Şimsek, Halis, Özdoğan, Osman, Çoban, Mehmet, Poturoğlu, Şule, Ayyıldız, Talat, Yapalı, Suna, Günsar, Fulya, Akdoğan, Meral, Özenirler, Seren, Akyıldız, Murat, Sezgin, Orhan, Kaymakoğlu, Sabahattin, Beşışık, Fatih, Karasu, Zeki, İdilman, Ramazan
Přispěvatelé:	Dicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıklar Ana Bilim Dalı, Gastroenteroloji & Hepatoloji Bölümü, Yalçın, Kendal, Dicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç HastalıklarAna Bilim Dalı, Degertekin B., Demir M., Akarca U. S., KANİ H. T., Ucbilek E., Yildirim E., Guzelbulut F., Balkan A., Vatansever S., DANIŞ N., et al., Acibadem University Dspace, Ege Üniversitesi
Jazyk:	angličtina
Rok vydání:	2020
Předmět:	Internal Diseases Cyclopropanes Male Sofosbuvir Turkey medicine.medical_treatment Hepacivirus Liver transplantation Sağlık Bilimleri Direct-acting antiviral medicine.disease_cause Gastroenterology İç Hastalıkları Clinical Medicine (MED) chemistry.chemical_compound Liver disease 0302 clinical medicine HEPATOCELLULAR-CARCINOMA INFECTION Klinik Tıp (MED) Anilides 030212 general & internal medicine Prospective Studies CIRRHOSIS Sulfonamides Klinik Tıp biology Original Article: Liver Valine Middle Aged GASTROENTEROLOJİ VE HEPATOLOJİ Tıp Hepatoloji Treatment Outcome SUSTAINED VIROLOGICAL RESPONSE HCV Medicine 030211 gastroenterology & hepatology Drug Therapy Combination Female RIBAVIRIN medicine.drug Ledipasvir medicine.medical_specialty Proline Hepatitis C virus Lactams Macrocyclic Direct-Acting Antiviral Gastroenterology and Hepatology Antiviral Agents ACTING ANTIVIRAL THERAPY 03 medical and health sciences Gastroenteroloji-(Hepatoloji) Internal medicine Health Sciences medicine Humans Aged Retrospective Studies Fluorenes Internal Medicine Sciences Ritonavir Hepatology business.industry GASTROENTEROLOGY & HEPATOLOGY Dahili Tıp Bilimleri CLINICAL MEDICINE Hepatitis C Chronic medicine.disease Gastroenteroloji Treatment chemistry Alanine transaminase Paritaprevir biology.protein Benzimidazoles Liver function business
Zdroj:	Turk J Gastroenterol
Popis:	Background/Aims: This study aimed to evaluate the real-life efficacy and tolerability of direct-acting antiviral treatments for patients with chronic hepatitis C (CHC) with/without cirrhosis in the Turkish population. Material and Methods: A total of 4,352 patients with CHC from 36 different institutions in Turkey were enrolled. They received ledipasvir (LDV) and sofosbuvir (SOF)+/- ribavirin (RBV) ombitasvir/paritaprevir/ritonavir +/- dasabuvir (PrOD)+/- RBV for 12 or 24 weeks. Sustained virologic response (SVR) rates, factors affecting SVR, safety profile, and hepatocellular cancer (HCC) occurrence were analyzed. Results: SVR12 was achieved in 92.8% of the patients (4,040/4,352) according to intention-to-treat and in 98.3% of the patients (4,040/4,108) according to per-protocol analysis. The SVR12 rates were similar between the treatment regimens (97.2%-100%) and genotypes (95.6%-100%). Patients achieving SVR showed a significant decrease in the mean serum alanine transaminase (ALT) levels (50.90 +/- 54.60 U/L to 17.00 +/- 14.50 U/L) and model for end-stage liver disease (MELD) scores (7.51 +/- 4.54 to 7.32 +/- 3.40) (p Turkish Association for the Study of The Liver (TASL) The present study was supported by The Turkish Association for the Study of The Liver (TASL).
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ead073c82203ad2e882eaa448290d1f8 https://europepmc.org/articles/PMC7928249/ Zobrazit plný text záznamu